A panel of experts reflect on the toxicity profiles of biologic agents used to treat patients with plaque psoriasis.
A focused discussion on the benefit of bimekizumab, an IL-17A/IL-17F inhibitor, in the setting of moderate to severe plaque psoriasis.
A brief review of biologic agents being used or evaluated in the setting of plaque psoriasis.
Taking a broader look at moderate to severe plaque psoriasis, experts consider what the standard of care would be in different settings.
The panel reviews therapeutic classes and their respective benefits in patients being treated for plaque psoriasis.
Centering discussion on a case of plaque psoriasis, experts share their experience with patient counseling and selecting therapy.
Considerations for the psychological and social impact that plaque psoriasis may have on a patient.
Panelists look deeper into the possible challenges or barriers to making an accurate diagnosis of plaque psoriasis
A study in the Journal of the American Academy of Dermatology examined the incidence of psoriasis according to body mass index.